SMT201700518T1 - Formulazione anestetica - Google Patents

Formulazione anestetica

Info

Publication number
SMT201700518T1
SMT201700518T1 SM20170518T SMT201700518T SMT201700518T1 SM T201700518 T1 SMT201700518 T1 SM T201700518T1 SM 20170518 T SM20170518 T SM 20170518T SM T201700518 T SMT201700518 T SM T201700518T SM T201700518 T1 SMT201700518 T1 SM T201700518T1
Authority
SM
San Marino
Prior art keywords
anaesthetic formulation
anaesthetic
formulation
Prior art date
Application number
SM20170518T
Other languages
English (en)
Italian (it)
Inventor
Juliet Marguerite Goodchild
Colin Stanley Goodchild
Benjamin James Boyd
Original Assignee
Drawbridge Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drawbridge Pharmaceuticals Pty Ltd filed Critical Drawbridge Pharmaceuticals Pty Ltd
Publication of SMT201700518T1 publication Critical patent/SMT201700518T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM20170518T 2010-01-21 2011-01-19 Formulazione anestetica SMT201700518T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22
EP11734245.1A EP2525798B1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
SMT201700518T1 true SMT201700518T1 (it) 2018-01-11

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20170518T SMT201700518T1 (it) 2010-01-21 2011-01-19 Formulazione anestetica

Country Status (27)

Country Link
US (2) US8697678B2 (enExample)
EP (1) EP2525798B1 (enExample)
JP (1) JP5930311B2 (enExample)
KR (1) KR101747476B1 (enExample)
CN (1) CN102802635B (enExample)
AU (1) AU2011207103B2 (enExample)
BR (1) BR112012017800B1 (enExample)
CA (1) CA2786762C (enExample)
CL (1) CL2012002032A1 (enExample)
CY (1) CY1119947T1 (enExample)
DK (1) DK2525798T3 (enExample)
ES (1) ES2646829T3 (enExample)
GB (2) GB2491491B (enExample)
HR (1) HRP20171699T1 (enExample)
HU (1) HUE035441T2 (enExample)
LT (1) LT2525798T (enExample)
NO (1) NO2525798T3 (enExample)
NZ (1) NZ601255A (enExample)
PL (1) PL2525798T3 (enExample)
PT (1) PT2525798T (enExample)
RS (1) RS56576B1 (enExample)
RU (1) RU2574022C2 (enExample)
SG (1) SG181997A1 (enExample)
SI (1) SI2525798T1 (enExample)
SM (1) SMT201700518T1 (enExample)
WO (1) WO2011088503A1 (enExample)
ZA (1) ZA201205370B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
EP2785352B1 (en) * 2011-11-29 2020-03-11 Jurox Pty Ltd Stable injectable pharmaceutical compositions comprising 2-hydroxypropyl-beta-cyclodextrin and alfaxalone
NZ773177A (en) * 2012-01-23 2022-09-30 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN115381772A (zh) * 2015-02-06 2022-11-25 马瑞纳斯制药公司 静脉内加奈索酮制剂及其用途
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US10780099B2 (en) * 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
WO2017156103A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. てんかん性障害の処置のための方法および組成物
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP6986140B2 (ja) 2018-04-16 2021-12-22 川崎重工業株式会社 ベルトコンベヤ
JP7443358B2 (ja) * 2018-07-03 2024-03-05 ドローブリッジ ファーマシューティカルズ ピーティーワイ リミテッド 神経活性ステロイドおよび調製の方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
US20220023314A1 (en) * 2018-12-10 2022-01-27 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
CA3158280A1 (en) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone for use in treating tuberous sclerosis complex
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69006259T2 (de) * 1989-05-24 1994-06-09 Innovet Inc Hypoallergene anästhesierende/hypnotische steroide Arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) * 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
MX2008006888A (es) * 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.

Also Published As

Publication number Publication date
BR112012017800A2 (en) 2018-07-10
BR112012017800B1 (pt) 2020-12-08
ES2646829T3 (es) 2017-12-18
RS56576B1 (sr) 2018-02-28
BR112012017800A8 (pt) 2018-08-14
HRP20171699T1 (hr) 2018-01-26
CY1119947T1 (el) 2018-12-12
DK2525798T3 (da) 2017-11-20
NO2525798T3 (enExample) 2018-01-06
US20140066417A1 (en) 2014-03-06
US8975245B2 (en) 2015-03-10
HUE035441T2 (en) 2018-05-02
RU2012134321A (ru) 2014-02-27
EP2525798A4 (en) 2014-02-19
GB2484244B (en) 2012-10-31
US20120316146A1 (en) 2012-12-13
HK1169031A1 (en) 2013-01-18
RU2574022C2 (ru) 2016-01-27
CA2786762A1 (en) 2011-07-28
GB2491491B (en) 2014-07-30
KR20120136347A (ko) 2012-12-18
CN102802635A (zh) 2012-11-28
AU2011207103A1 (en) 2012-07-26
PT2525798T (pt) 2017-11-15
JP5930311B2 (ja) 2016-06-08
EP2525798A1 (en) 2012-11-28
CA2786762C (en) 2017-12-05
NZ601255A (en) 2013-09-27
PL2525798T3 (pl) 2018-05-30
SI2525798T1 (en) 2018-01-31
EP2525798B1 (en) 2017-08-09
GB201210657D0 (en) 2012-08-01
CL2012002032A1 (es) 2012-12-21
SG181997A1 (en) 2012-08-30
LT2525798T (lt) 2018-01-10
US8697678B2 (en) 2014-04-15
KR101747476B1 (ko) 2017-06-14
GB2484244A (en) 2012-04-04
AU2011207103B2 (en) 2013-03-21
WO2011088503A1 (en) 2011-07-28
GB2491491A (en) 2012-12-05
ZA201205370B (en) 2013-09-25
CN102802635B (zh) 2014-07-30
JP2013517299A (ja) 2013-05-16
GB201201842D0 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
GB2484244B (en) Anaesthetic formulation
GB201010193D0 (en) Medicinal use
PL2865271T3 (pl) Ulepszony preparat
ZA201206589B (en) Incotine containing formulation
LT2642980T (lt) Pediatrinė vaisto forma
ZA201300194B (en) Formulations
GB201110193D0 (en) Formulations
GB201013513D0 (en) Formulations
GB201012721D0 (en) Headgear-mountable respirator
GB201011138D0 (en) Vaporiser
GB201006326D0 (en) Formulation
ZA201300196B (en) Formulations
HK1169031B (en) Anaesthetic formulation
GB201005992D0 (en) Formulation
GB201001978D0 (en) Formulation
GB201002000D0 (en) Formulation
PL393180A1 (pl) Preparat weterynaryjny
PL390421A1 (pl) Preparat weterynaryjny
GB201018647D0 (en) Formulations
GB201018649D0 (en) Formulations
GB201018648D0 (en) Formulations
GB201007702D0 (en) Formulations
GB201018645D0 (en) Formulations
GB201007959D0 (en) Formulations
GB201012589D0 (en) Formulations